Journal article
Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection
MS Parsons, SB Lloyd, WS Lee, AB Kristensen, T Amarasena, RJ Center, BF Keele, JD Lifson, CC La Branche, D Montefiori, BD Wine, PM Hogarth, KM Swiderek, V Venturi, MP Davenport, SJ Kent
Science Translational Medicine | Published : 2017
Abstract
Broadly neutralizing antibodies (BnAbs) protect macaques from cell-free simian/human immunodeficiency virus (SHIV) challenge, but their efficacy against cell-associated SHIV is unclear. Virus in cell-associated format is highly infectious, present in transmission-competent bodily fluids, and potentially capable of evading antibody-mediated neutralization. The PGT121 BnAb, which recognizes an epitope consisting of the V3 loop and envelope glycans, mediates antibody-dependent cellular cytotoxicity and neutralization of cell-to-cell HIV-1 transmission. To evaluate whether a BnAb can prevent infection after cell-associated viral challenge, we infused pigtail macaques with PGT121 or an isotype co..
View full abstractRelated Projects (1)
Grants
Awarded by National Cancer Institute
Funding Acknowledgements
This work was supported by grants from the Australian Centre for HIV and Hepatitis Virology Research (ACH2), awards from the Australian National Health and Medical Research Council, and a fellowship (to M.S.P.) from the Canadian Institutes of Health Research and, in part, federal funds from the National Cancer Institute, NIH, under contract no. HHSN261200800001E. Macaque MHC typing was supported by the Wisconsin National Primate Research Center base grant from the National Center for Research Resources (P51 RR000167) and the Office of Research Infrastructure Programs (P51 OD011106) of the NIH.